TBPH
Price:
$16.58
Market Cap:
$854.75M
Theravance Biopharma, Inc. is a biopharmaceutical firm focused on discovering, developing, and bringing to market treatments for respiratory conditions across North America, Europe, and Asia. Its portfolio features YUPELRI, a daily, nebulized long-acting muscarinic antagonist (LAMA) prescribed for chronic obstructive pulmonary disease (COPD). The company also maintains a substantial pipeline of experimental medications. Izencitinib, a gut-targeted pan-janus kinase (JAK) inhibitor, is undergoing Phase IIb/III trials for its potential in treating rheumatoid arthritis, myelofibrosis, and various inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Ampreloxetine, an inves...[Read more]
Industry
Biotechnology
IPO Date
2014-05-16
Stock Exchange
NASDAQ
Ticker
TBPH
According to Theravance Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 7.43. This represents a change of 81.30% compared to the average of 4.10 of the last 4 quarters.
The mean historical PE Ratio of Theravance Biopharma, Inc. over the last ten years is -5.24. The current 7.43 PE Ratio has changed -14290.59% with respect to the historical average. Over the past ten years (40 quarters), TBPH's PE Ratio was at its highest in in the September 2025 quarter at 52.14. The PE Ratio was at its lowest in in the March 2026 quarter at -42.18.
Average
-5.24
Median
-6.25
Minimum
-11.24
Maximum
8.91
Discovering the peaks and valleys of Theravance Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 143.82%
Maximum Annual PE Ratio = 8.91
Minimum Annual Increase = -208.88%
Minimum Annual PE Ratio = -11.24
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 8.91 | -208.88% |
| 2024 | -8.18 | -27.20% |
| 2023 | -11.24 | 26.22% |
| 2022 | -8.90 | 131.28% |
| 2021 | -3.85 | -3.37% |
| 2020 | -3.98 | -34.60% |
| 2019 | -6.09 | -5.02% |
| 2018 | -6.41 | 25.33% |
| 2017 | -5.12 | -31.62% |
| 2016 | -7.48 | 143.82% |
The current PE Ratio of Theravance Biopharma, Inc. (TBPH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.50
5-year avg
-4.65
10-year avg
-5.24
Theravance Biopharma, Inc.’s PE Ratio is less than BlackRock Technology and Private Equity Term Trust (54.94), greater than Monte Rosa Therapeutics, Inc. (-9.84), greater than Day One Biopharmaceuticals, Inc. (-20.70), greater than Geron Corporation (-12.08), greater than Replimune Group, Inc. (-2.85), greater than Vir Biotechnology, Inc. (-2.93), greater than LENZ Therapeutics, Inc. (-1.71), greater than ArriVent BioPharma, Inc. Common Stock (-8.99), greater than Valneva SE (-2.84), greater than Tyra Biosciences, Inc. (-12.99),
| Company | PE Ratio | Market cap |
|---|---|---|
| 54.94 | $1.09B | |
| -9.84 | $1.19B | |
| -20.70 | $2.22B | |
| -12.08 | $808.32M | |
| -2.85 | $841.41M | |
| -2.93 | $1.54B | |
| -1.71 | $192.83M | |
| -8.99 | $1.48B | |
| -2.84 | $510.15M | |
| -12.99 | $1.68B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theravance Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Theravance Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Theravance Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Theravance Biopharma, Inc. (TBPH)?
What is the highest PE Ratio for Theravance Biopharma, Inc. (TBPH)?
What is the 3-year average PE Ratio for Theravance Biopharma, Inc. (TBPH)?
What is the 5-year average PE Ratio for Theravance Biopharma, Inc. (TBPH)?
How does the current PE Ratio for Theravance Biopharma, Inc. (TBPH) compare to its historical average?